Finasteride in the Prevention of Prostate Cancer Progression

The study evaluated the use of 5 α reductase inhibitors, specifically finasteride, in 96 patients with low-risk prostate cancer under active surveillance from 2008 to 2015. The treatment aimed to reduce disease progression and improve urinary symptoms. Results showed a 23% reduction in prostate size, improved urination, and enhanced quality of life. The average time to disease progression by PSA level was 32.2 months, with histological progression in 16.7% of patients. A total of 27.1% of patients underwent radical treatment due to progression or personal choice. The study concluded that 5 α reductase inhibitors effectively reduced prostate volume and improved diagnostic sensitivity, with a lower progression rate and fewer patients abandoning active surveillance.